Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Cipla
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Cipla and Formosa Sign Multi-Regional Licensing Deal for Clobetasol Suspension
Details : Cipla has rights to market the innovative treatment, APP13007, a novel, patent protected and USFDA approved ophthalmic product, for post-operative inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
March 18, 2025
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Cipla
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Medvisis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa & Medvisis Announce Licensing Deal for Clobetasol
Details : Under the license agreement, Medvisis will obtain rights of APP13007 (clobetasol propionate) in Switzerland and Liechtenstein for the post-operative inflammation & pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
November 28, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Medvisis
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : DAVI Farmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa And DÁVI License Clobetasol for Post-Operative Pain Therapy
Details : Under the term license agreement, DAVI will gain the exclusive rights to commercialize APP13007 (clobetasol propionate) for the treatment of inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
October 31, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : DAVI Farmaceutica
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Tabuk Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk for Clobetasol
Details : Tabuk gains rights to APP13007 (clobetasol propionate) for post-ocular surgery pain and inflammation in the MENA region.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Tabuk Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable
Formosa and Eyenovia Begin Co-Development of Clobetasol for Acute Dry Eye Disease
Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of dry eye disease.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
July 08, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Eyenovia
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Announce Licensing Agreement with Apotex for Clobetasol Propionate
Details : Through the licensing agreement, Apotex will gain exclusive rights of APP13007 (clobetasol propionatei) in Canada for commercialization to treat inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
May 08, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Apotex Inc
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Formosa and AimMax Receive FDA Approval for Clobetasol Propionate Suspension
Details : APP13007 (clobetasol propionate) is a nanoparticle ophthalmic formulation of a steroid. It is approved for the treatment of post-operative inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
April 03, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Formosa Pharmaceuticals Licenses APP13007 for Inflammation and Pain Post-Ocular Surgery
Details : Under the agreement, Cristália gets exclusive Brazilian rights for commercializing APP13007 (clobetasol propionate ophthalmic nanosuspension) for inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
January 26, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Cristalia Produtos Quimicos Farma. Ltda
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Through the acquisition, Eyenovia has gained the exclusive U.S. rights to distribute and sell APP13007 (clobetasol propionate ophthalmic nanosuspension), a potent steroid for reducing the inflammation and pain associated with ocular surgery, which is und...
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
August 16, 2023
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Eyenovia
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : APP13007 (clobetasol propionate ophthalmic nanosuspension) is expected to provide ophthalmologists and ocular surgery patients with a compelling, rapid and sustained, and more convenient postoperative anti-inflammatory and pain relief solution.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : AimMax Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable